Please do not adjust margins
MedChemComm
Page 13 of 15
DOI: 10.1039/C7MD00568G
Journal Name
ARTICLE
3
4
K. D. Deane and H. El-Gabalawy, Nat. Rev. Rheumatol., 2014, 32 R. J. Riese, S. Krishnaswami and J. Kremer, Best Pract. Res.
10, 212. Clin. Rheumatol., 2010, 24, 513.
P. Jacques and F. Van den Bosch, Expert Opin. Emerg. Drugs, 33 European Medicines Agency. Refusal of the marketing
2013, 18, 231.
authorisation for Xeljanz (tofacitinib), EMA/248755/2013,
EMEA/H/C/002542, 25. April 2013,
Summary_of_opinion_-
5
6
P. Emery, Nat. Rev. Rheumatol., 2015, 11, 69.
F. M. P. Meier, M. Frerix, W. Hermann and U. Müller-Ladner,
Immunotherapy, 2013, 5, 955.
7
8
9
G. R. Burmester, E. Feist and T. Dorner, Nat. Rev.
Rheumatol., 2014, 10, 77.
E. Neumann, K. Khawaja and U. Muller-Ladner, Nat. Rev. 34 B. W. Dymock, E. G. Yang, Y. Chu-Farseeva and L. Yao, Future
_Initial_authorisation/human/002542/WC500142485.pdf,
(accessed September 2017).
Rheumatol., 2014, 10, 429.
S. Müller and S. Knapp, Expert Opin. Drug Discov., 2010,
Med. Chem., 2014, 6, 1439.
5,
35 D. L. Boyle, K. Soma, J. Hodge, A. Kavanaugh, D. Mandel, P.
Mease, R. Shurmur, A. K. Singhal, N. Wei, S. Rosengren, I.
Kaplan, S. Krishnaswami, Z. Luo, J. Bradley and G. S. Firestein,
Ann. Rheum. Dis., 2015, 74, 1311.
867.
10 V. Kelly and M. Genovese, Rheumatology, 2013, 52, 1155.
11 J. K. Buer, Inflammopharmacology, 2015, 23, 163.
12 T. Doan and E. Massarotti, J. Clin. Pharmacol., 2005, 45, 751.
13 J. R. O'Dell, N. Engl. J. Med., 2004, 350, 2591.
36 C. J. Menet, O. Mammoliti and M. López-Ramos, Future Med.
Chem., 2015, 7, 203.
14 J. Detert and P. Klaus, Biologics, 2015,
9
, 35.
37 Menet, C. J. M.; Van Rompaey, L. J. C.; Fletcher, S.R.; Blanc, J.;
Jouannigot, N.; Hodges, A. J.; Smits, K. K. PCT Int. Appl. WO
2010010190 A1, 2010.
15 A. Mócsai, L. Kovács and P. Gergely, BMC Med., 2014, 12, 43.
16 A. F. Wilks, Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 1603.
17 J. Darnell, I. Kerr and G. Stark, Science, 1994, 264, 1415.
38 J. Gras, Drug. Future, 2014, 39, 547.
18 K. Shuai and B. Liu, Nat. Rev. Immunol., 2003,
19 K. Ghoreschi, A. Laurence and J. J. O’Shea, Immunol. Rev.,
2009, 228, 273.
20 P. S. Changelian, M. E. Flanagan, D. J. Ball, C. R. Kent, K. S.
Magnuson, W. H. Martin, B. J. Rizzuti, P. S. Sawyer, B. D.
3
, 900.
39 C. J. Menet, S. R. Fletcher, G. Van Lommen, R. Geney, J.
Blanc, K. Smits, N. Jouannigot, P. Deprez, E. M. van der Aar,
P. Clement-Lacroix, L. Lepescheux, R. Galien, B. Vayssiere, L.
Nelles, T. Christophe, R. Brys, M. Uhring, F. Ciesielski and L.
Van Rompaey, J. Med. Chem., 2014, 57, 9323.
Perry, W. H. Brissette, S. P. McCurdy, E. M. Kudlacz, M. J. 40 L. Van Rompaey, R. Galien, E. M. van der Aar, P. Clement-
Conklyn, E. A. Elliott, E. R. Koslov, M. B. Fisher, T. J. Strelevitz,
K. Yoon, D. A. Whipple, J. Sun, M. J. Munchhof, J. L. Doty, J.
M. Casavant, T. A. Blumenkopf, M. Hines, M. F. Brown, B. M.
Lillie, C. Subramanyam, C. Shang-Poa, A. J. Milici, G. E.
Lacroix, L. Nelles, B. Smets, L. Lepescheux, T. Christophe, K.
Conrath, N. Vandeghinste, B. Vayssiere, S. De Vos, S.
Fletcher, R. Brys, G. van ’t Klooster, J. H. M. Feyen and C.
Menet, J. Immunol., 2013, 191, 3568.
Beckius, J. D. Moyer, C. Su, T. G. Woodworth, A. S. Gaweco, 41 P. Norman, Expert Opin. Investig. Drugs, 2014, 23, 1067.
C. R. Beals, B. H. Littman, D. A. Fisher, J. F. Smith, P. 42 Filgotinib Versus Placebo in Adults With Active Rheumatoid
Zagouras, H. A. Magna, M. J. Saltarelli, K. S. Johnson, L. F.
Nelms, S. G. Des Etages, L. S. Hayes, T. T. Kawabata, D. Finco-
Kent, D. L. Baker, M. Larson, M.-S. Si, R. Paniagua, J. Higgins,
B. Holm, B. Reitz, Y.-J. Zhou, R. E. Morris, J. J. O'Shea and D.
C. Borie, Science, 2003, 302, 875.
Arthritis (RA) Who Have an Inadequate Response to Biologic
Disease-modifying Anti-rheumatic Drug(s) (DMARDs)
(Identification No. NCT02873936).
43 Filgotinib Alone and in Combination With Methotrexate
(MTX) in Adults With Moderately to Severely Active
Rheumatoid Arthritis Who Are Naive to MTX Therapy.
No. NCT02886728).
21 D. M. Meyer, M. I. Jesson, X. Li, M. M. Elrick, C. L. Funckes-
Shippy, J. D. Warner, C. J. Gross, M. E. Dowty, S. K. Ramaiah,
J. L. Hirsch, M. J. Saabye, J. L. Barks, N. Kishore and D. L.
Morris, J. Inflamm., 2010, 7, 41.
22 M. E. Dowty, M. I. Jesson, S. Ghosh, J. Lee, D. M. Meyer, S. 44 Filgotinib in Combination With Methotrexate in Adults With
Krishnaswami and N. Kishore, J. Pharmacol. Exp. Ther., 2014,
348, 165.
23 E. Feist and G. R. Burmester, Rheumatology, 2013, 52, 1352.
24 B. Bannwarth, M. Kostine and N. Poursac, Expert Opin. Drug
Moderately to Severely Active Rheumatoid Arthritis Who
Have an Inadequate Response to Methotrexate. (2016).
NCT02889796).
Metab. Toxicol., 2013,
9
, 753.
45 Galapagos NV. Risks related to product development,
commercialization,
25 J. M. Kremer, B. J. Bloom, F. C. Breedveld, J. H. Coombs, M. P.
Fletcher, D. Gruben, S. Krishnaswami, R. Burgos-Vargas, B.
Wilkinson, C. A. F. Zerbini and S. H. Zwillich, Arthritis Rheum.,
2009, 60, 1895.
regulatory
approval
and
factors/product-development-regulatory-approval-and-
commercialization.html, (accessed September 2017).
26 US Food and Drug Administration. Center for drug evaluation 46 A Study Comparing ABT-494 to Placebo and to Adalimumab
and research, Application number: 203214Orig1s000,
Approval letter,
/203214Orig1s000MedR.pdf, (Accessed September 2017).
27 H. Neubauer, A. Cumano, M. Müller, H. Wu, U. Huffstadt and
K. Pfeffer, Cell, 1998, 93, 397.
28 D. E. Levy and C. A. Loomis, N. Engl. J. Med., 2007, 357, 1655.
29 S. O. Park, H. L. Wamsley, K. Bae, Z. Hu, X. Li, S.-w. Choe, W.
B. Slayton, S. P. Oh, K.-U. Wagner and P. P. Sayeski, PLoS
in Subjects With Rheumatoid Arthritis Who Are on a Stable
Dose of Methotrexate and Who Have an Inadequate
Response to Methotrexate (SELECT-COMPARE). (2015).
NCT02629159)
47 A Study Comparing ABT-494 Monotherapy to Methotrexate
(MTX) Monotherapy in Subjects With Rheumatoid Arthritis
(RA) Who Have an Inadequate Response to MTX (SELECT-
MONOTHERAPY).
(2016).
Retrieved
from
One, 2013,
30 A. Tefferi, Blood, 2012, 119, 2721.
31 A. Pardanani, J. R. Gotlib, C. Jamieson, J. E. Cortes, M. Talpaz,
R. M. Stone, M. H. Silverman, D. G. Gilliland, J. Shorr and A.
Tefferi, J. Clin. Oncol., 2011, 29, 789.
8
, e59675.
48 M. C. Genovese, J. S. Smolen, M. E. Weinblatt, G. R.
Burmester, S. Meerwein, H. S. Camp, L. Wang, A. A. Othman,
N. Khan, A. L. Pangan and S. Jungerwirth, Clin. Exp.
Rheumatol., 2016, 34, 318.
This journal is © The Royal Society of Chemistry 20xx
J. Name., 2013, 00, 1-3 | 13
Please do not adjust margins